Grunenthal's New Approach To R&D

Life Science Leader Newsletter

MARCH 10, 2015 Grünenthal Builds A New Entrepreneurial And Networked Approach To R&D By Rob Wright, chief editor, Life Science Leader magazine Grünenthal recognizes that to develop a sustainable business model it must adopt an open and collaborative approach to R&D. But how is a company the size of Grünenthal supposed to compete for R&D partners? Implementing a new entrepreneurial specialist and networked approach to R&D is key, says CSO Klaus Langner. Read more. CAPITOL PERSPECTIVES  Treasury Threatens Small Businesses For Providing Health Coverage In The "Wrong Way" By John McManus, president and founder, The McManus Group As if the challenge of providing healthcare coverage is not difficult enough for small businesses, the Department of Treasury is now threatening to penalize any employer who provides tax-preferred resources for their employees to purchase insurance coverage in the individual market with a $36,500 annual fee per employee. Read more. FEATURE  Cubist: The Curtain Closes By Wayne Koberstein, executive editor, Life Science Leader magazine By the end of 2014, Cubist's fate was sealed but still uncertain in at least one respect: Would it maintain its identity as Merck's wholly-owned subsidiary or ultimately meld away into Big Pharma Merck, having left its indelible mark on the history of antibiotics? Read more. FINANCE  The R&D Tax Credit — A Catalyst For Life Sciences Innovation By Yair Holtzman, CPA, MBA, MS, partner, Anchin, Block & Anchin LLP Does your company develop new medical products, pharmaceuticals, or innovative production techniques in the United States? Does your company invest resources toward optimizing manufacturing processes? If so, your company may qualify for the R&D Tax Credit, an often overlooked and misunderstood opportunity. Read more. A Recipe For Life Sciences Commercialization By Roger Humphrey, executive managing director, JLL's Life Sciences Group As the landscape of the biopharmaceutical industry expands into growing regions an exciting transformation is beginning to transfer commercialization "recipes" to emerging markets. All eyes are on small, specialty, and midsize players emerging at the forefront of innovation in the mature regions of Europe and the United States. Read more. BIOTECH INSIGHTS  How An Executive's Health Challenges Can Make A Biotech Stronger By Brad Thompson, Ph.D., president and CEO, Oncolytics Biotech Inc. As the CEO of a biotech company since 1994, people often ask what has kept me focused throughout my 20-year (and counting) tenure. Aside from my firm belief in the value of the cancer treatments we are studying, there is another motivation: a personal experience with this terrible disease. Read more.